# Amgen, Inc. - Inspection Records

Source: https://www.keypedia.com/companies/amgen-inc/85ec512e-6991-42ee-9cd5-148cfe0ed3e8

> Inspection records and compliance data for Amgen, Inc. in Thousand Oaks, California. Access full analysis and detailed observations.

---

## Details

- Name: Amgen, Inc.
- FEI Number: 2026154
- City: Thousand Oaks
- State: California
- Country Name: United States
- Address Line 1: 1 Amgen Center Dr
- Zip Code: 91320

## Related Documents

- [483 - Amgen, Inc. - Unknown Date](https://www.keypedia.com/records/483/amgen-inc/a1384fcb-8ceb-4fff-b827-7aedea6283ba) — source: FDA, date: Invalid Date
- [483 - Amgen, Inc. - Unknown Date](https://www.keypedia.com/records/483/amgen-inc/0f69de0e-3c79-4e80-8482-84801428e3f1) — source: FDA, date: Invalid Date
- [483 - Amgen, Inc. - Unknown Date](https://www.keypedia.com/records/483/amgen-inc/3fd38f88-0f27-4242-95c6-59ba05cffdc8) — source: FDA, date: Invalid Date
- [CRL - Amgen, Inc. - Unknown Date](https://www.keypedia.com/records/crl/amgen-inc/b96aeb10-a857-41b8-8fa5-8ca2465cce5a) — source: FDA, date: Invalid Date
- [FDA Inspection 1278976 - Amgen, Inc. - 2025-08-07](https://www.keypedia.com/records/fda_inspections/amgen-inc/d97d8a62-a229-4000-9007-f563754eede5) — source: FDA, date: August 7, 2025
- [FDA Inspection 1278976 - Amgen, Inc. - 2025-08-07](https://www.keypedia.com/records/fda_inspections/amgen-inc/41a4234d-3f2f-4bab-ab8b-9a1e17008055) — classification: No Action Indicated (NAI), source: FDA, date: August 7, 2025
- [483 - Amgen, Inc. - 2025-03-13](https://www.keypedia.com/records/483/amgen-inc/f158a248-7fa2-44df-9ef9-74b5f972894b) — source: FDA, date: March 13, 2025
- [FDA Inspection 1256132 - Amgen, Inc. - 2025-03-13](https://www.keypedia.com/records/fda_inspections/amgen-inc/8601b5a4-a27d-4f90-9399-1e0398db8be7) — classification: Voluntary Action Indicated (VAI), source: FDA, date: March 13, 2025
- [FDA Inspection 1220409 - Amgen, Inc. - 2023-09-14](https://www.keypedia.com/records/fda_inspections/amgen-inc/78815a66-7fde-4e3c-b744-48f87db72016) — classification: No Action Indicated (NAI), source: FDA, date: September 14, 2023
- [483 - Amgen, Inc. - 2019-12-13](https://www.keypedia.com/records/483/amgen-inc/38972f72-b21d-41b2-bb8b-25e715f425e9) — source: FDA, date: December 13, 2019
- [EIR - Amgen, Inc. - 2019-12-13](https://www.keypedia.com/records/eir/amgen-inc/7155ec06-4efb-4490-8b2d-eecd030871d1) — source: FDA, date: December 13, 2019
- [FDA Inspection 1112791 - Amgen, Inc. - 2019-12-13](https://www.keypedia.com/records/fda_inspections/amgen-inc/f7c02d35-9f41-4022-9b49-996bf75204ed) — classification: Voluntary Action Indicated (VAI), source: FDA, date: December 13, 2019
- [FDA Inspection 1028320 - Amgen, Inc. - 2017-08-21](https://www.keypedia.com/records/fda_inspections/amgen-inc/e1905cc5-73ce-4b78-91c5-b5621663675b) — classification: No Action Indicated (NAI), source: FDA, date: August 21, 2017
- [483 - Amgen, Inc. - 2017-05-16](https://www.keypedia.com/records/483/amgen-inc/a23066f5-45d7-4383-9490-ac82f211990c) — source: FDA, date: May 16, 2017
- [FDA Inspection 1014808 - Amgen, Inc. - 2017-04-19](https://www.keypedia.com/records/fda_inspections/amgen-inc/07317c73-f6bc-4986-a1e3-67eb147496c1) — classification: No Action Indicated (NAI), source: FDA, date: April 19, 2017
- [FDA Inspection 1014825 - Amgen, Inc. - 2017-04-19](https://www.keypedia.com/records/fda_inspections/amgen-inc/1623f72b-121b-4bed-b0fa-6ddf83e70f7a) — classification: No Action Indicated (NAI), source: FDA, date: April 19, 2017
- [FDA Inspection 1008341 - Amgen, Inc. - 2017-03-17](https://www.keypedia.com/records/fda_inspections/amgen-inc/89a303a8-e43d-46f4-b05e-110ccdd0b68d) — classification: No Action Indicated (NAI), source: FDA, date: March 17, 2017
- [FDA Inspection 989425 - Amgen, Inc. - 2016-09-01](https://www.keypedia.com/records/fda_inspections/amgen-inc/59c02d8e-81ef-46c4-9a0c-10effda01566) — classification: No Action Indicated (NAI), source: FDA, date: September 1, 2016
- [WARNING_LETTER - Amgen, Inc. - 2013-06-17](https://www.keypedia.com/records/warning_letter/amgen-inc/980f4f23-54ec-4bfd-b859-cf7b7d38566c) — source: FDA, date: June 17, 2013

## Related Companies

- [Nordmark Arzneimittel GMBH & Co. KG](https://www.keypedia.com/companies/nordmark-arzneimittel-gmbh-co-kg/871eb270-8517-4646-923a-b4d2eb0ea73b)
- [Baxalta Belgium Manufacturing SA](https://www.keypedia.com/companies/baxalta-belgium-manufacturing-sa/61b3acce-a147-4f22-b13a-34bb436ea8e9)
- [Cilag AG](https://www.keypedia.com/companies/cilag-ag/acb7f670-89b9-4e40-a784-ed06b0282362)
- [Bristol-Myers Squibb Company](https://www.keypedia.com/companies/bristol-myers-squibb-company/b20ef646-d409-4268-af48-ddf4c16f82cc)
- [Aprecia Pharmaceuticals LLC](https://www.keypedia.com/companies/aprecia-pharmaceuticals-llc/126049a3-6c3d-4616-8d44-006827a308c3)
- [Advanced Accelerator Applications (Italy) srl](https://www.keypedia.com/companies/advanced-accelerator-applications-italy-srl/09ac059c-6735-4082-8674-a88476dbdbc6)
- [AgroChem USA, LLC](https://www.keypedia.com/companies/agrochem-usa-llc/007b3455-bf3c-4d23-b1e7-0be79ebba21e)
- [OMRIX Biopharmaceuticals LTD](https://www.keypedia.com/companies/omrix-biopharmaceuticals-ltd/bf1b8f1e-b1c7-47be-bb38-f85e1cff944d)
- [Merck Sharp & Dohme LLC](https://www.keypedia.com/companies/merck-sharp-dohme-llc/842c6e25-ee89-453c-a5b0-6b039c187744)
- [Shionogi Pharma Co., Ltd.](https://www.keypedia.com/companies/shionogi-pharma-co-ltd/bb3e5dcd-52f9-4971-9747-4c04b63ba0fa)

## Related Officers

- [Marc Kubasak, PhD](https://www.keypedia.com/people/marc-kubasak-phd/0022703d-5fa9-4022-9d76-821be46e8f5d)
- [company_representative](https://www.keypedia.com/people/aine-hanly/0dbf31ef-cd0c-42a8-9526-2af63d970b49)
- [company_representative](https://www.keypedia.com/people/joe-beaty/44d99207-36ca-48e3-a144-4e7c2bbfba70)
- [issuing_officer](https://www.keypedia.com/people/jee-y-chung/0736677f-9719-44dc-9dab-60b610ac1a0a)
- [investigator](https://www.keypedia.com/people/laura-fontan/b27b02a3-9ab1-49df-b2bc-ee936b69d76a)